已关闭
  • 文献求助详情
标题
Real life targeted therapies alone or in combination in brain metastases patients: French experience within MelBase
网址
求助人暂未提供
DOI
暂未提供,该求助的时间将会延长,查看原因?
其它 Melanoma brain metastases (BM) result in poor prognosis. Targeted therapies (TT) showed significant efficacy in monotherapy (Vemurafenib V/Dabrafenib D) and in combination (V+Cobimetinib VC/D+Trametinib DT). Encouraging data from BM treated by TT com-bination were reported. We present original results of efficacy and tol-erance in real life BM treated with TT (V/D, VC/DT) in French MelBase. It is a multicentric clinical biobank dedicated to prospective follow-up (FU) of unresectable stage III or IV melanoma adults. 1168 patients are included. Available data were collected (June 2017) and analyzed: monotherapy (gA), combination (gB). The characteristics are: gA (n = 58): mean age 58 years (48-70), PS 0-1 81%, LDH>ULN 36%, ≥3 metastatic organ sites (MOS) 60%, treated in 1st line 67%. gB (n = 64): mean age 56 years (45-64), PS 0-1 90%, LDH>ULN 39%, ≥3 MOS 63%, treated in 1st line 70%. After median FU 7.3 months (mos), median OS is 8.3 mos (95% CI:6.8-11.8;gA), 15.1 months (95% CI:7.7-NR;gB); median PFS is 4.0 mos (95% CI:3.5-5.6;gA), 6.6 mos (95% CI:5.5-8.1;gB). BORR is 31% (gA), 41% (gB); DCR is 64% (gA;gB). Age, LDH, PS, BM, radiotherapy (RT) were tested in univariate analysis. Multivariate analysis on global population (with treatment stratification) indicates that LDH (adjusted HR 1.9, 95% CI: 1.2-3.3), PS (aHR 3.6, 95% CI: 1.9-6.8), RT (aHR 2.3, 95% CI: 1.3-4.2) are significantly associated with OS; PS (aHR 3.0, 95% CI: 1.6-5.5), BM (aHR 1.5, 95% CI: 1.0-2.4) are significantly associated with PFS. OS and PFS seem similar to already published data (Davies 2017) in both groups. Adding anti-MEK increases BORR but not DCR. It increases PFS and OS but less than in patients without BM. It is the 1st study evaluating prognostic factors and pointing out RT as a good factor in multivariate analysis. Concomitant stereotaxic RT should systematically be discussed in BM patients treated by TT.
求助人
不吃早饭的猪猪子 在 2020-09-18 17:45:38 发布,悬赏 10 积分
下载
求助 / 应助时间线
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
light完成签到 ,获得积分10
刚刚
大模型应助聆听采纳,获得10
刚刚
sff完成签到,获得积分10
2秒前
guojingjing发布了新的文献求助10
2秒前
2秒前
又见三皮完成签到,获得积分10
4秒前
一行白鹭上青天完成签到 ,获得积分10
4秒前
zzz完成签到,获得积分10
4秒前
shenzhou9完成签到,获得积分10
4秒前
灰色与青完成签到,获得积分10
7秒前
zhuww完成签到,获得积分10
7秒前
Answer完成签到,获得积分10
8秒前
Akim应助苦酷采纳,获得10
8秒前
zvk完成签到,获得积分10
8秒前
十六完成签到,获得积分10
9秒前
9秒前
直率一刀发布了新的文献求助30
9秒前
zho应助科研如喝水采纳,获得10
10秒前
岚12完成签到 ,获得积分10
11秒前
镜哥完成签到,获得积分10
11秒前
机智幻嫣应助19111867526采纳,获得10
11秒前
sssss应助keyan123采纳,获得10
13秒前
Eason完成签到 ,获得积分10
13秒前
NIHAO213发布了新的文献求助10
15秒前
嘒彼小星完成签到 ,获得积分10
16秒前
1234567xjy完成签到,获得积分10
17秒前
难过大白完成签到 ,获得积分10
18秒前
21秒前
24秒前
Milton_z完成签到 ,获得积分10
24秒前
雨落瑾年完成签到,获得积分10
27秒前
酷波er应助yiyimx采纳,获得10
27秒前
28秒前
28秒前
苦酷发布了新的文献求助10
29秒前
tzjz_zrz完成签到,获得积分10
29秒前
30秒前
隐形山芙发布了新的文献求助10
32秒前
王博士完成签到,获得积分10
35秒前
36秒前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2700
Neuromuscular and Electrodiagnostic Medicine Board Review 1000
こんなに痛いのにどうして「なんでもない」と医者にいわれてしまうのでしょうか 510
The First Nuclear Era: The Life and Times of a Technological Fixer 500
Unusual formation of 4-diazo-3-nitriminopyrazoles upon acid nitration of pyrazolo[3,4-d][1,2,3]triazoles 500
岡本唐貴自伝的回想画集 500
Distinct Aggregation Behaviors and Rheological Responses of Two Terminally Functionalized Polyisoprenes with Different Quadruple Hydrogen Bonding Motifs 450
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3671625
求助须知:如何正确求助?哪些是违规求助? 3228325
关于积分的说明 9779625
捐赠科研通 2938636
什么是DOI,文献DOI怎么找? 1610180
邀请新用户注册赠送积分活动 760547
科研通“疑难数据库(出版商)”最低求助积分说明 736093